Anteris is a clinical-stage structural-heart company building the DurAVR transcatheter valve and advancing the global pivotal PARADIGM trial toward commercialization. The company recently raised substantial capital to fund that development, so this filing is about aligning senior management with a high-risk, multi-year execution plan—not reporting a new clinical or regulatory milestone.
The proposed package is unusually large and not yet effective. Wayne Paterson and David St Denis would receive 1.614 million stock options plus 1.285 million performance-based restricted stock units, but the awards remain contingent on shareholder approval. 〔0〕 〔1〕 That makes the immediate business impact limited, while putting shareholders on notice of potentially meaningful future dilution and compensation expense.
The PSU structure ties most of the upside to major stock-price hurdles. Thirty percent of each grant vests at a $21.50 60-day VWAP, another 30% at $41.00, and the final 40% at $61.50. This creates strong incentive alignment if Anteris successfully advances DurAVR, but it is a market-value target rather than a direct clinical, regulatory, or revenue milestone.
The options add retention value while preserving a performance gate through continued employment. Paterson and St Denis would generally vest over four years, while Matthew McDonnell receives a separate option award with a stated target value of $500,000 and three-year vesting. 〔2〕 The change-in-control provisions also accelerate vesting in certain circumstances, which protects executives during a sale but could increase the cost of a transaction.
Bottom line: This is a meaningful governance and dilution event, but not a change to Anteris’s clinical or commercial trajectory yet. The key question is whether shareholders approve a large package whose value depends on retaining management and achieving much higher market valuations.
Read the original 8-K on SEC EDGAR ↗